Home LiteratureArticle Details
PMID: 19079136 Published · ppublish English Journal Article Review

Harnessing invariant NKT cells in vaccination strategies.

Nature reviews. Immunology ·Vol. 9 ·No. 1 ·2009-01-00 ·Pages 28-38

Cerundolo V, Silk JD, Masri SH, Salio M

Abstract

To optimize vaccination strategies, it is important to use protocols that can 'jump-start' immune responses by harnessing cells of the innate immune system to assist the expansion of antigen-specific B and T cells. In this Review, we discuss the evidence indicating that invariant natural killer T (iNKT) cells can positively modulate dendritic cells and B cells, and that their pharmacological activation in the presence of antigenic proteins can enhance antigen-specific B- and T-cell responses. In addition, we describe structural and kinetic analyses that assist in the design of optimal iNKT-cell agonists that could be used in the clinical setting as vaccine adjuvants.

MeSH Terms
Adjuvants, Immunologic Animals Antigens, CD1d/chemistry,immunology B-Lymphocytes/immunology Cell Differentiation Clinical Trials as Topic Cytokines/metabolism Dendritic Cells/immunology Forecasting Galactosylceramides/chemistry,pharmacology,therapeutic use Glycolipids/immunology Humans Immunity, Innate Immunologic Surveillance/immunology Infections/immunology Lymphocyte Activation Mice Models, Molecular Natural Killer T-Cells/drug effects,immunology Neoplasms/immunology,therapy Receptors, Antigen, T-Cell, alpha-beta/immunology Structure-Activity Relationship Vaccination/methods
Chemicals
Adjuvants, Immunologic Antigens, CD1d Cytokines Galactosylceramides Glycolipids Receptors, Antigen, T-Cell, alpha-beta alpha-galactosylceramide
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Cerundolo Vincenzo
Tumour Immunology Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DU, UK. vincenzo.cerundolo@imm.ox.ac.uk
Silk Jonathan D
Masri S Hajar
Salio Mariolina
References (127)
127 references, click to expand
  1. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency.
    Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1849-54 PMID: 12576547
  2. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
    J Exp Med. 2003 Jul 21;198(2):267-79 PMID: 12874260
  3. Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells.
    J Am Chem Soc. 2004 Oct 27;126(42):13602-3 PMID: 15493902
  4. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells.
    Eur J Immunol. 2005 Jun;35(6):1692-701 PMID: 15915536
  5. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.
    J Clin Invest. 2008 Mar;118(3):994-1005 PMID: 18259610
  6. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity.
    Blood. 2002 Jul 1;100(1):11-6 PMID: 12070001
  7. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers.
    J Exp Med. 2000 Sep 4;192(5):741-54 PMID: 10974039
  8. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
    J Immunol. 2004 Sep 15;173(6):3693-706 PMID: 15356115
  9. Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d.
    J Immunol Methods. 2007 May 31;323(1):11-23 PMID: 17442335
  10. Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids.
    J Mol Biol. 2008 Apr 4;377(4):1104-16 PMID: 18295796
  11. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
    J Gen Virol. 2007 Jan;88(Pt 1):1-12 PMID: 17170430
  12. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells.
    J Immunol. 2007 Mar 1;178(5):2721-9 PMID: 17312114
  13. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
    J Immunol. 2004 Jan 15;172(2):943-53 PMID: 14707067
  14. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.
    J Exp Med. 2005 May 2;201(9):1503-17 PMID: 15867097
  15. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population.
    Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11287-92 PMID: 18685112
  16. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Clin Cancer Res. 2005 Mar 1;11(5):1910-7 PMID: 15756017
  17. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids.
    PLoS Biol. 2005 Apr;3(4):e113 PMID: 15799695
  18. IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2.
    Blood. 2005 Jul 1;106(1):184-92 PMID: 15746081
  19. Invariant NKT cells amplify the innate immune response to lipopolysaccharide.
    J Immunol. 2007 Mar 1;178(5):2706-13 PMID: 17312112
  20. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
    J Immunol. 2003 Mar 1;170(5):2540-8 PMID: 12594280
  21. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor.
    Nature. 2007 Jul 5;448(7149):44-9 PMID: 17581592
  22. Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice.
    J Clin Invest. 2008 Jun;118(6):2301-15 PMID: 18451996
  23. Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation.
    Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20490-5 PMID: 18077358
  24. Differential tumor surveillance by natural killer (NK) and NKT cells.
    J Exp Med. 2000 Feb 21;191(4):661-8 PMID: 10684858
  25. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
    J Immunol. 2003 Nov 15;171(10):5140-7 PMID: 14607913
  26. Natural Sphingomonas glycolipids vary greatly in their ability to activate natural killer T cells.
    Chem Biol. 2008 Jul 21;15(7):654-64 PMID: 18635002
  27. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.
    Blood. 2008 Jun 15;111(12):5637-45 PMID: 18417738
  28. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals.
    Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5971-6 PMID: 17372214
  29. Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells.
    Eur J Immunol. 2008 Apr;38(4):1012-23 PMID: 18350544
  30. Differential antitumor immunity mediated by NKT cell subsets in vivo.
    J Exp Med. 2005 Nov 7;202(9):1279-88 PMID: 16275765
  31. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining.
    J Exp Med. 2002 Mar 4;195(5):625-36 PMID: 11877485
  32. The crystal structure of human CD1d with and without alpha-galactosylceramide.
    Nat Immunol. 2005 Aug;6(8):819-26 PMID: 16007090
  33. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria.
    Nat Immunol. 2006 Sep;7(9):978-86 PMID: 16921381
  34. Distinct functional lineages of human V(alpha)24 natural killer T cells.
    J Exp Med. 2002 Mar 4;195(5):637-41 PMID: 11877486
  35. NKT cell ligand alpha-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation.
    Eur J Immunol. 2004 Sep;34(9):2471-9 PMID: 15307179
  36. OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice.
    J Clin Invest. 2007 Nov;117(11):3330-8 PMID: 17975668
  37. NK T cells provide lipid antigen-specific cognate help for B cells.
    Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8339-44 PMID: 18550809
  38. Germline-encoded recognition of diverse glycolipids by natural killer T cells.
    Nat Immunol. 2007 Oct;8(10):1105-13 PMID: 17828267
  39. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.
    J Clin Invest. 2004 Dec;114(12):1800-11 PMID: 15599405
  40. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells.
    J Immunol. 2008 May 15;180(10):6452-6 PMID: 18453560
  41. Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
    Nat Rev Cancer. 2008 Apr;8(4):299-308 PMID: 18354418
  42. A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR.
    J Exp Med. 2008 Apr 14;205(4):939-49 PMID: 18378792
  43. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo.
    J Immunol. 2005 Apr 15;174(8):4696-705 PMID: 15814694
  44. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Clin Cancer Res. 2002 Dec;8(12):3702-9 PMID: 12473579
  45. Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.
    Immunology. 2008 Jan;123(1):145-55 PMID: 18154620
  46. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers.
    J Exp Med. 2000 Jun 5;191(11):1895-903 PMID: 10839805
  47. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Vaccine. 2008 Mar 28;26(15):1807-16 PMID: 18329757
  48. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge.
    J Immunol. 2005 Sep 1;175(5):3092-3101 PMID: 16116198
  49. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide.
    J Exp Med. 2004 Apr 5;199(7):947-57 PMID: 15051763
  50. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes.
    J Exp Med. 2003 Apr 21;197(8):1051-7 PMID: 12695492
  51. Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells.
    J Immunol. 1998 Nov 15;161(10):5124-8 PMID: 9820479
  52. T cell anergy.
    Annu Rev Immunol. 2003;21:305-34 PMID: 12471050
  53. The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition.
    Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12254-9 PMID: 15304644
  54. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity.
    Blood. 2004 Jan 15;103(2):383-9 PMID: 14512316
  55. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.
    Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10299-304 PMID: 17566107
  56. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.
    Mucosal Immunol. 2008 May;1(3):208-18 PMID: 19079180
  57. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor.
    Nat Immunol. 2005 Aug;6(8):810-8 PMID: 16007091
  58. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
    Nat Rev Immunol. 2005 Jan;5(1):31-42 PMID: 15630427
  59. Role of NK1.1+ T cells in a TH2 response and in immunoglobulin E production.
    Science. 1995 Dec 15;270(5243):1845-7 PMID: 8525383
  60. Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells.
    J Immunol. 2008 Apr 1;180(7):4615-20 PMID: 18354184
  61. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography.
    Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3294-8 PMID: 11248072
  62. CD1-dependent dendritic cell instruction.
    Nat Immunol. 2002 Dec;3(12):1163-8 PMID: 12415264
  63. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion.
    Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10913-8 PMID: 12960397
  64. Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry.
    Glycobiology. 2008 Feb;18(2):158-65 PMID: 18056651
  65. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.
    Nat Immunol. 2002 Sep;3(9):867-74 PMID: 12154358
  66. Invariant NKT cells sustain specific B cell responses and memory.
    Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3984-9 PMID: 17360464
  67. Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules.
    J Exp Med. 1999 Oct 18;190(8):1069-80 PMID: 10523605
  68. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
    J Immunol. 2005 Sep 1;175(5):3309-17 PMID: 16116223
  69. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells.
    Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10685-90 PMID: 15243159
  70. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.
    J Clin Invest. 2008 Dec;118(12):4036-48 PMID: 19033672
  71. A structural basis for immunodominant human T cell receptor recognition.
    Nat Immunol. 2003 Jul;4(7):657-63 PMID: 12796775
  72. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide.
    J Exp Med. 2003 Dec 1;198(11):1631-41 PMID: 14657217
  73. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.
    Nature. 2005 Mar 24;434(7032):525-9 PMID: 15791258
  74. Lysosomal glycosphingolipid recognition by NKT cells.
    Science. 2004 Dec 3;306(5702):1786-9 PMID: 15539565
  75. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d.
    Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):3972-7 PMID: 16537470
  76. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells.
    J Immunol. 2003 Sep 1;171(5):2571-80 PMID: 12928408
  77. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis.
    J Immunol. 2008 Mar 15;180(6):3627-35 PMID: 18322166
  78. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
    Int J Cancer. 2005 Jan 10;113(2):259-66 PMID: 15386406
  79. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice.
    J Exp Med. 1995 Oct 1;182(4):993-1004 PMID: 7561702
  80. Recognition of bacterial glycosphingolipids by natural killer T cells.
    Nature. 2005 Mar 24;434(7032):520-5 PMID: 15791257
  81. NKT cells: what's in a name?
    Nat Rev Immunol. 2004 Mar;4(3):231-7 PMID: 15039760
  82. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.
    Nature. 2001 Oct 4;413(6855):531-4 PMID: 11586362
  83. Peripheral NK1.1 NKT cells are mature and functionally distinct from their thymic counterparts.
    J Immunol. 2007 Nov 15;179(10):6630-7 PMID: 17982053
  84. Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis.
    Int J Mol Med. 2008 Sep;22(3):369-74 PMID: 18698497
  85. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells.
    J Immunol. 1999 Nov 1;163(9):4647-50 PMID: 10528160
  86. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection.
    Nat Immunol. 2003 Dec;4(12):1230-7 PMID: 14578883
  87. Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.
    Eur J Immunol. 2008 Mar;38(3):829-40 PMID: 18253930
  88. NKT cells and autoimmune diseases: unraveling the complexity.
    Curr Top Microbiol Immunol. 2007;314:251-67 PMID: 17593664
  89. Rapid NKT cell responses are self-terminating during the course of microbial infection.
    J Immunol. 2008 Aug 15;181(4):2292-302 PMID: 18684918
  90. Murine CD1d-restricted T cell recognition of cellular lipids.
    Immunity. 2000 Feb;12(2):211-21 PMID: 10714687
  91. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system.
    Curr Opin Immunol. 2008 Jun;20(3):358-68 PMID: 18501573
  92. Liver autoimmunity triggered by microbial activation of natural killer T cells.
    Cell Host Microbe. 2008 May 15;3(5):304-15 PMID: 18474357
  93. Structure and binding kinetics of three different human CD1d-alpha-galactosylceramide-specific T cell receptors.
    J Exp Med. 2006 Mar 20;203(3):699-710 PMID: 16520393
  94. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
    Immunity. 2007 Oct;27(4):597-609 PMID: 17950005
  95. Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation.
    PLoS Biol. 2008 Jul 15;6(7):e172 PMID: 18630988
  96. Control points in NKT-cell development.
    Nat Rev Immunol. 2007 Jul;7(7):505-18 PMID: 17589542
  97. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.
    Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11252-7 PMID: 16844772
  98. Dendritic cells in a mature age.
    Nat Rev Immunol. 2006 Jun;6(6):476-83 PMID: 16691244
  99. DNA vaccines: progress and challenges.
    J Immunol. 2005 Jul 15;175(2):633-9 PMID: 16002657
  100. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide.
    Blood. 2002 Sep 1;100(5):1728-33 PMID: 12176894
  101. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.
    J Exp Med. 2007 May 14;204(5):1131-44 PMID: 17485514
  102. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected].
    J Immunol. 2003 Nov 1;171(9):4539-51 PMID: 14568927
  103. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice.
    J Med Chem. 1995 Jun 9;38(12):2176-87 PMID: 7783149
  104. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells.
    J Immunol. 2003 Oct 15;171(8):4020-7 PMID: 14530322
  105. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia.
    J Exp Med. 2007 May 14;204(5):995-1001 PMID: 17470641
  106. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.
    J Exp Med. 2002 Mar 4;195(5):617-24 PMID: 11877484
  107. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.
    Science. 1997 Nov 28;278(5343):1626-9 PMID: 9374463
  108. The fidelity, occasional promiscuity, and versatility of T cell receptor recognition.
    Immunity. 2008 Mar;28(3):304-14 PMID: 18342005
  109. The terminology issue for myeloid-derived suppressor cells.
    Cancer Res. 2007 Jan 1;67(1):425; author reply 426 PMID: 17210725
  110. Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
    J Exp Med. 2005 Apr 18;201(8):1243-55 PMID: 15837811
  111. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion.
    J Immunol. 2008 Apr 15;180(8):5167-71 PMID: 18390697
  112. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells.
    J Clin Invest. 2004 Jun;113(11):1631-40 PMID: 15173890
  113. Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets.
    J Immunol. 2003 Sep 15;171(6):2960-9 PMID: 12960320
  114. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation.
    J Exp Med. 2004 Jun 21;199(12):1607-18 PMID: 15197224
  115. A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan.
    J Exp Med. 2004 Oct 4;200(7):895-904 PMID: 15466622
  116. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency.
    Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5977-82 PMID: 17372206
  117. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells.
    J Exp Med. 1998 Oct 19;188(8):1529-34 PMID: 9782130
  118. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6079-86 PMID: 17028247
  119. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides.
    Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3383-8 PMID: 15722411
  120. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion.
    Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1127-32 PMID: 15644449
  121. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
    Cancer Immunol Immunother. 2008 Mar;57(3):337-45 PMID: 17690880
  122. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.
    J Exp Med. 2002 Jul 1;196(1):119-27 PMID: 12093876
  123. Structural and functional aspects of lipid binding by CD1 molecules.
    Annu Rev Cell Dev Biol. 2008;24:369-95 PMID: 18593354
  124. Glycolipids for natural killer T cells.
    Chem Soc Rev. 2006 Sep;35(9):771-9 PMID: 16936925
  125. Glycolipid antigen induces long-term natural killer T cell anergy in mice.
    J Clin Invest. 2005 Sep;115(9):2572-83 PMID: 16138194
  126. Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation.
    Int Immunol. 2004 Feb;16(2):241-7 PMID: 14734609
  127. B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo.
    Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8345-50 PMID: 18550831
Article Info
Journal
Nature reviews. Immunology
Abbr.
Nat Rev Immunol
ISSN
1474-1741
DOI
10.1038/nri2451
Email
vincenzo.cerundolo@imm.ox.ac.uk
Published
2009-01-00
Pages
28-38
Language
English
Region
England
NLM ID
101124169
Subset
IM
Grants
Cancer Research UK · 11331 · United Kingdom
External Links
PubMed source DOI: 10.1038/nri2451 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2